Meningococcal Infections: all 243 studies

Page 2 of 3. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.

• Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year OldsCompletedNCT01154088Phase 3Results posted
• Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10CompletedNCT01148524Phase 2/3Results posted
• Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib VaccinesCompletedNCT01144663Phase 3Results posted
• One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of AgeCompletedNCT01139021Phase 3Results posted
• A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in IndiaCompletedNCT01086969Phase 3Results posted
• A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and ToddlersCompletedNCT01049035Phase 2Results posted
• Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same VaccineCompletedNCT01027351Phase 2Results posted
• Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same VaccineCompletedNCT01026974Phase 2Results posted
• A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWYCompletedNCT01018732Phase 2Results posted
• A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 MonthsCompletedNCT01000311Phase 3Results posted
• Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612CompletedNCT00974363Phase 3Results posted
• Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612CompletedNCT00955682Phase 3Results posted
• Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12CompletedNCT00944034Phase 2/3Results posted
• Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old InfantsCompletedNCT00937521Phase 2Results posted
• Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 YearsCompletedNCT00874549Phase 1/2Results posted
• Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® VaccineCompletedNCT00862277Results posted
• Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®CompletedNCT00850603Phase 4Results posted
• Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy ToddlersCompletedNCT00847145Phase 3Results posted
• Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy InfantsCompletedNCT00806195Phase 3Results posted
• Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in AdolescentsCompletedNCT00777790Phase 2Results posted
• Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap VaccineCompletedNCT00777257Phase 4Results posted
• Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy AdultsTerminatedNCT00772629Phase 2Results posted
• Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate VaccineCompletedNCT00772070Phase 2Results posted
• Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in ChildrenCompletedNCT00771849Phase 2Results posted
• Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual AdministrationCompletedNCT00758264Phase 3Results posted
• 36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year OldsCompletedNCT00728260Results posted
• Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization SchedulesCompletedNCT00721396Phase 2Results posted
• The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy ToddlersCompletedNCT00718666Phase 2Results posted
• The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/AdultsCompletedNCT00715910Phase 2Results posted
• Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26CompletedNCT00700713Phase 2Results posted
• Dose Comparison Study of Menactra® in US ChildrenCompletedNCT00700635Phase 2Results posted
• Phase 1 Safety and Immunogenicity of Meningococcal VaccineCompletedNCT00678652Phase 1Results posted
• Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy ChildrenCompletedNCT00674583Phase 3Results posted
• Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination SchedulesCompletedNCT00661713Phase 2/3Results posted
• Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated SubjectsCompletedNCT00661557Phase 2Results posted
• Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy InfantsCompletedNCT00657709Phase 3Results posted
• Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of AgeCompletedNCT00643916Phase 2Results posted
• Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy ToddlersCompletedNCT00626327Phase 3Results posted
• Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy ChildrenCompletedNCT00616421Phase 3Results posted
• Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014CompletedNCT00614614Phase 3Results posted
• Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 MonthsCompletedNCT00601731Phase 2Results posted
• Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk AdultsCompletedNCT00560313Phase 2Results posted
• Immunology and Safety of Menactra® in Children in Saudi ArabiaCompletedNCT00539032Phase 3Results posted
• Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old SubjectsCompletedNCT00514904Phase 3Results posted
• Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each VaccineCompletedNCT00508261Phase 3Results posted
• Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850ACompletedNCT00496015Phase 3Results posted
• B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy InfantsCompletedNCT00488683Phase 2Results posted
• A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In InfantsCompletedNCT00474526Phase 3Results posted
• A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy AdultsCompletedNCT00474487Phase 3Results posted
• Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old ChildrenCompletedNCT00474266Phase 3Results posted
• Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.CompletedNCT00471081Phase 2Results posted
• Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612CompletedNCT00465816Phase 3Results posted
• Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old SubjectsCompletedNCT00464815Phase 3Results posted
• Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same VaccinesCompletedNCT00463437Phase 3Results posted
• Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.CompletedNCT00454909Phase 2Results posted
• Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old AdultsCompletedNCT00453986Phase 3Results posted
• A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and AdultsCompletedNCT00450437Phase 3Results posted
• Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi ArabiaCompletedNCT00444951Phase 3Results posted
• Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy InfantsCompletedNCT00433914Phase 2Results posted
• Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612CompletedNCT00427908Phase 2Results posted
• Immunogenicity of the Booster Dose of Two MenC VaccinesCompletedNCT00392808Phase 4Results posted
• Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy StudyCompletedNCT00381615Phase 2Results posted
• Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate VaccineCompletedNCT00356369Phase 2Results posted
• Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 YearsCompletedNCT00329901Phase 3Results posted
• Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of AgeCompletedNCT00329849Phase 3Results posted
• Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed SubjectsCompletedNCT00317109Phase 3Results posted
• Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 StudyCompletedNCT00291343Phase 3Results posted
• Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 YearsCompletedNCT00290329Phase 4Results posted
• Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate VaccineCompletedNCT00289783Phase 3Results posted
• Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®CompletedNCT00269477Phase 2Results posted
• Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy AdolescentsCompletedNCT00262041Phase 2Results posted
• Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy ChildrenCompletedNCT00262028Phase 2Results posted
• Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy InfantsCompletedNCT00262002Phase 2Results posted
• Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®CompletedNCT00258856Phase 2Results posted
• Descriptive, Post-marketing, Surveillance Safety Study of Menactra VaccineCompletedNCT00254995Results posted
• Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years OldCompletedNCT00196976Phase 2Results posted
• Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal VaccineCompletedNCT00129129Phase 2Results posted
• Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in ChinaCompletedNCT07135986Phase 3
• Azithromycin for Meningococcal CarriageCompletedNCT06618534Phase 2
• A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of AgeActive, not recruitingNCT06113198Phase 4
• Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years OldCompletedNCT05739292Phase 1
• A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, ItalyStatus unknownNCT05212935
• Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years OldCompletedNCT04714229Phase 1
• Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT)Status unknownNCT04398849
• Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of AgeCompletedNCT04358731Phase 2/3
• Propositive (Protecting Positive People From Meningococcal Infection) Follow-up StudyStatus unknownNCT04239430
• Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.CompletedNCT04236960Phase 1
• Enhanced Population-based Core Surveillance of Meningococcal Invasive Infections at Participating Centers Across CanadaStatus unknownNCT04184336
• Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody AssaysStatus unknownNCT04023929
• The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young AdultsCompletedNCT03798574
• Adolescent MenACWY Booster StudyCompletedNCT03694405Phase 4
• Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.CompletedNCT03378258
• Babies Born Early Antibody Response to Men B Vaccination: BEAR Men BCompletedNCT03125616Phase 4
• South Australian Meningococcal B Vaccine Herd Immunity StudyCompletedNCT03089086Phase 4
• Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of AgeStatus unknownNCT02919293Phase 1/2
• Postmarketing Surveillance Study for Use of Menactra® in the Republic of KoreaCompletedNCT02864927Phase 4
• PRIME Follow up - Quadri Meningo VacineesCompletedNCT02811120
• Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of ImmunizationCompletedNCT02712177
• Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian FederationCompletedNCT02699840
• Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up StudyCompletedNCT02500511

← Meningococcal Infections overview